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Abstract
Telomerase is a ribonucleoprotein enzyme that compensates for the telomere length shortening
which occurs during the cell cycle. Telomerase activity has been detected in most tumours but not
in somatic cells. However, hTR; the RNA component of telomerase; has been reported to be
universally expressed in both cancerous and non-cancerous tissues. Tumour samples from 50
patients with primary invasive breast cancer were collected. The TRAP assay was used to detect
telomerase activity. RT-PCR on cDNA and DNased cDNA samples and control groups was used
to detect the expression of hTR, GAPDH and PGM1 genes. Seventy-two percent of samples
showed telomerase activity. DNA contamination was detected in 36 (72%) of RNA samples.
Without performing DNase treatment, 49 (98%) of all samples showed hTR expression, but with
the application of this strategy, hTR expression decreased from 98% to 64%. A significant
association (p < 0.001) between hTR expression and telomerase activity was observed. Among the
32 hTR positive samples, 30 had telomerase activity and among the 18 hTR negative samples,
telomerase activity was observed in 6 cases. Thus the application of this strategy could provide an
applicable tool to use instead of the TRAP assay thus facilitating telomerase research in cancer
genetic investigations.
Introduction
Telomerase is a ribonucleoprotein that compensates the
shortening of the ends of eukaryotic chromosomes occur-
ring during the cell cycle. This RNA-dependent DNA
polymerase provides the basis for an unlimited prolifera-
tion. Its activity is absent in most normal human somatic
cells, including breast tissue, but is present in over 90% of
cancerous cells and in vitro-immortalized cells [1-14]. Tel-
omerase consists of two fundamental components, an
RNA component (in humans, hTR or hTERc) and a reverse
transcriptase component (hTERT) [15].
The RNA component of telomerase acts as the template
for telomeric repeat synthesis. In man, hTR is transcribed
by RNA polymerase II and its mature transcript consists of
451 nucleotides [16]. The hTR gene was cloned and local-
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ized to chromosome 3q26.3. in 1998 [17,18]. The tem-
plate for hTERT activity lies in nucleotides 46 to 53.
Although there is a variation of hTR RNA sequences
among telomerase RNAs, there is a remarkably conserved
secondary structure from ciliates to vertebrates. This indi-
cates an essential role for the structure in enzyme function
[19]. hTR is a single-copy gene that lacks poly A and does
not contain any introns, so RT-PCR for hTR gene is con-
sidered to be prone to errors. DNA contamination of RNA
extractions could be amplified by PCR and therefore
could give rise to a false positive result for hTR transcrip-
tion affecting the correlation between hTR expression and
telomerase activity [20,21]
Materials and methods
Patients
Institutional guidelines including ethical approval and
informed consent were followed. We investigated 50
tumour samples from patients with primary invasive
breast cancer treated surgically during 2004–2005 at
Tehran University of Medical Sciences. Breast tissues were
collected and preserved by rapid freezing in liquid nitro-
gen immediately after surgical excision and then were
stored at -70°C.
The TRAP assay
Telomerase activity was analyzed using the PCR-based tel-
omeric-repeat amplification protocol (TRAP assay) as pre-
viously described [22].
The frozen samples (50 mg) were homogenized in 100 µl
chaps lysis buffer (10 mM Tris-HCl (pH 8.3), 1 mM
MgCl2, 1 mM EGTA, 5 mM β-mercaptoethanol, 0.5%
CHAPS, 10% Glycerol and 0.1 mM PMSF (β-mercaptoeth-
anol and PMSF were added before use).
After incubation for 30 minutes on ice, the lysate was cen-
trifuged for 20 min at 12,000 g at 4°C, and then, the
supernatant was immediately stored at -70°C. Aliquots of
0.5 to 5 µg of protein were incubated with 30 µl of a reac-
tion mixture containing 20 mM Tris-HCl (pH 8.3), 1.5
mM MgCl2, 63 mM KCl, 0.05% Tween 20, 1 mM EGTA
(TitriplexVI, Merck, USA), 125 µM dNTPs and 50 ng of TS
primer (5'- AATCCGTCGAGCAGAGTT-3') in a thermocy-
cler for 35 min at 30°C for generation of telomeric repeats
(presence or absence of T4gene32protein did not affect
the results.). To avoid probable RNase activity, mineral oil
was added in the last minuets, by denaturation at 94°C
for 5 min (for inactivating telomerase activity) and pre-
serving at 70°C, 2.5 U Taq DNA polymerase (Roche, Ger-
many), 50 ng of ACX primer (5'-
GCGCGG(CTTACC)3CTAACC-3'), 50 ng of NT internal
control primer (5'-ATCGCTTCTCGGCCTTTT-3') and 1.3
× 10-9ng of TSNT internal control (5'-AATCCGTC-
GAGCGCAGAGGTTAAAAGGCCGAGAAGCGAT-3') were
added. Then, the mixture was subjected to 35 PCR cycles
at 94°C for 30 s, 56°C for 45 s, and 72°C for 45 s.
The PCR products were mixed with a loading dye and elec-
trophoresed on 10% non-denaturing polyacrylamide gel,
and finally, stained by silver nitrate which has more sensi-
tivity than SYBR Green and Ethidium bromide.
An internal control was used to detect false-negative sam-
ples containing PCR inhibitors (such as CHAPS). In order
to avoid false-positive results (characterized by variation
in band intensity), negative controls were used. It was pro-
duced by heating the protein extract for 5 min at 90–95°C
(to remove the enzyme activity) or using any telomerase
negative sample (Fig. 1).
RT-PCR analysis
Total RNA was isolated from samples using Tripure Isola-
tion Reagent (Roche, Germany). One microgram of total
RNA, with random hexamer and M-Mulv reverse tran-
scriptase enzyme (Fermentas co, Canada.) were used to
create cDNA for each sample, according to the manufac-
turer's protocol. In order to avoid he probable DNA con-
tamination for RNA samples, the following stages were
performed. We prepared a solution containing the same
Telomerase activity detected by TRAP assay method Figure 1
Telomerase activity detected by TRAP assay 
method. C.-: A negative control group including a telomer-
ase negative sample, a denatured protein sample and a mix-
ture without protein extract.Journal of Carcinogenesis 2006, 5:17 http://www.carcinogenesis.com/content/5/1/17
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materials used for cDNA synthesis excluding reverse tran-
scriptase enzyme (negative control 1). This product con-
tains DNA only, with a new concentration similar to the
cDNA products, however, in the PCR products of these
samples, the presence or absence of any DNA contamina-
tion could be observed and detected.
In order to perform DNase treatment, 1 µg of total RNA
was digested by DNaseI (Fermentas Co, Canada) accord-
ing to the manufacturer's protocol. Half of DNase treated
RNA sample was used to create cDNA. The remaining half
of the sample contained all of the materials excluding the
reverse transcriptase enzyme (negative control 2), in order
to validate the accuracy of DNase treatment process.
The cDNA, DNase treated cDNA and two control group
samples were amplified in a 25 µl reaction mixture con-
taining 0.2 µM of each primers and 1U Taq DNA polymer-
ase (Fermentas co., Canada). GAPDH was amplified using
GapF (5'-GGGAAGGT GAAGGTCGGAGTC-3') and GapR
(5'-AGCAGAGGGGGCAGA GATGAT-3') oligonucle-
otides with an initial heating at 95°C for 3 min, followed
by 30 cycles of 94°C for 45 s, 63°C for 45 s, and 72°C for
45 s. Due to the existence of GAPDH pseudogene and its
amplification in DNA samples as well as cDNA, and to
avoid its false positive results (will be explained in discus-
sion), the PGM1 (Phosphoglucomutase1) a housekeep-
ing gene was used as a control which could detect the
presence of cDNA in the samples. PGM1 was amplified
using PGM1-F (5'-TCCGACTGAGCGGCACT-
GGGAGTGC-3')and PGM1-R (GCCCGCAGGTCC TCTT-
TCCCTCACA-3') oligonucleotides with 30 cycles of 94°C
for 30 s, 63°C for 30 s, and 72°C for 30 s. hTR was ampli-
fied using TR-F (5'-CGCCGTGCTTTTGCT CC-3') and TR-
R (5'-ACTCGCTCCGTTCCTCTTCC-3') oligonucleotides
for 5 cycles of 94°C for 1 min, 63°C for 1 min, and 72°C
for 1 min, followed by 30 cycles of 94°C for 45 s, 63°C
for 50 s, and 72°C for 45 s. Amplified products were sub-
jected to electrophoresis in 2% agarose gels and were vis-
ualized with ethidium bromide.
Statistical analysis
The statistical analysis of the data was carried out by using
the SPSS software package (SPSS Inc; Chicago, IL, USA;
Version 11.5, 2003). The Pearson, Chi-square and Fisher
Exact tests were used. The significance levels were consid-
ered for results with P value less than 0.05.
Results
Telomerase activity was detected in 36 out of 50 (72%)
samples (Table 1). The hTR gene expression was observed
in 32 (64%) samples of which 30 (93.7%) samples had
telomerase activity. In 6 (33%) samples without hTR
expression, telomerase activity was detected (Table 2).
There was a significant association between telomerase
activity and hTR expression (Chi square = 20.85, p
<0.001).
By using GAPDH primers in the control products (nega-
tive control groups 1 and 2), it was observed that 36
(72%) RNA extracts had DNA contamination. In total, 36
samples (with DNA contamination) demonstrated hTR
expression in cDNA samples, whereas after DNase treat-
ment, 17 samples did not show hTR expression.
The hTR expression in cDNAs was observed in 49 out of
50 (98%) samples, of which, 35 had telomerase activity.
In one case without any DNA contamination and with tel-
omerase activity, hTR expression in cDNA and DNased
cDNA samples was not observed.
In cDNA samples with negative results for GAPDH-PCR,
the hTR – PCR was found to be negative, which confirms
the lack of any DNA contamination (Table 1).
Discussion
GAPDH has a psuedogene which could be amplified with
GAPDH cDNA primers, as well as the current GAPDH
gene cDNA. Usually, RNA is contaminated with DNA and
due to the performance of PCR on a negative control
group (this product has only probable DNA contamina-
tion), it will create a positive result that arises from the
presence of a pseudogene in the sample(Fig. 2). The
present subject was not considered in most studies in
which the GAPDH housekeeping gene was used as a pos-
itive control to assess the accuracy of cDNA synthesis. In
fact, the positive result of GAPDH-PCR may be due to the
amplification of the pseudogene and not to the cDNA
template. If GAPDH primers are used for DNA samples,
then positive results will be occur. In this regard, this char-
acteristic of GAPDH was used to ensure the accuracy of
DNase treatment procedures.
When the result of GAPDH-PCR was positive in DNased
treated cDNA samples, and negative in negative control
group 2, then it can be assumed that the existing templates
in DNased treated samples are cDNA and are not the
result of any DNA contamination.
The inactivation of DNase enzyme seems to be another
problem in DNase treatment procedures. If a high temper-
ature is used for denaturation of the enzyme, this would
affect the RNA molecules, and if DNase enzyme denatur-
ation is not completely performed, it would have an effect
on PCR performance of the samples. In the present inves-
tigation, all of the treated samples with DNase enzyme
were checked with GAPDH as well as with PGM1 house-
keeping genes for detecting the presence of cDNA and
were, finally, subjected to PCR for the hTR gene.Journal of Carcinogenesis 2006, 5:17 http://www.carcinogenesis.com/content/5/1/17
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Table 1: The characteristic results of the TRAP assay and RT-PCR on PGM1, GAPDH and hTR genes.
PGM1 GAPDH hTR
No. Telomera
se activity
cDNA DNased 
cDNA
cDNA RNA 
withoutRT*
DNased 
cDNA
DN-RNA 
withoutRT**
cDNA RNA 
withoutRT*
DNased 
cDNA
DN-RNA 
withoutRT**
1+++ + + + - + + + -
2+++ + + + - + + - -
3+++ + + + - + + + -
4+++ + - + - + - + -
5+++ + + + - + + + -
6-++ + + + - + + - -
7-++ + + + - + + + -
8+++ + + + - + + + -
9-++ + + + - + + - -
1 0 +++ + - + - + - + -
1 1 +++ + + + - + + - -
1 2 +++ + + + - + + - -
1 3 +++ + - + - + - + -
1 4 +++ + - + - - - - -
1 5 +++ + + + - + + + -
1 6 +++ + + + - + + + -
1 7 +++ + + + - + + + -
18 - + + + + + - + + - -
19 - + + + + + - + + - -
20 - + + + + + - + + - -
2 1 +++ + + + - + + + -
2 2 +++ + - + - + - + -
23 - + + + + + - + + - -
2 4 +++ + - + - + - + -
2 5 +++ + + + - + + + -
2 6 +++ + - + - + - + -
2 7 +++ + + + - + + - -
28 - + + + - + - + - + -
2 9 +++ + - + - + - + -
30 - + + + + + - + + - -
3 1 +++ + - + - + - + -
32 - + + + + + - + + - -
3 3 +++ + - + - + - + -
34 - + + + + + - + + - -
35 - + + + + + - + + - -
36 - + + + + + - + + - -
3 7 +++ + + + - + + + -
3 8 +++ + - + - + - + -
3 9 +++ + + + - + + + -
4 0 +++ + + + - + + + -
4 1 +++ + + + - + + + -
4 2 +++ + - + - + - + -
4 3 +++ + + + - + + - -
4 4 +++ + + + - + + + -
4 5 +++ + + + - + + + -
4 6 +++ + + + - + + + -
4 7 +++ + + + - + + + -
4 8 +++ + - + - + - + -
4 9 +++ + + + - + + + -
50 - + + + + + - + + - -
*: Mixture of RNA and materials required for cDNA synthesis without Reverse Transcriptase enzyme, determining the probable DNA 
contamination.
**: Mixture of DNased RNA and materials required for cDNA synthesis without Reverse Transcriptase enzyme, determining the accuracy of 
DNase treatment.Journal of Carcinogenesis 2006, 5:17 http://www.carcinogenesis.com/content/5/1/17
Page 5 of 6
(page number not for citation purposes)
Most investigators [2-4,11-13,23-27] have not paid any
attention to the lack of intron of hTR gene. Therefore, the
reported results were representative of a high expression
of this gene and hence no association could be observed
between hTR expression and telomerase activity (Table 3).
Furthermore, the effect of the probable remaining DNase
activity post DNase enzyme inactivation was not noticed
in previous studies using DNase treatment [27].
In this study, the accuracy of the procedures, including
DNase treatment and cDNA synthesis and creating nega-
tive control groups were checked with GAPDH and PGM1
housekeeping genes. In the case of having a positive result
for negative control groups, or a negative result for DNase
treated cDNAs, then the repeat of the DNase treatment
and use of negative control groups would be required.
A false estimation of our result, through a procedure with-
out DNase treatment, would be expected, i.e., instead of
observing 49 (98%) with hTR expression, the outcome
could be decreased to 64%.
Table 3: The results of some previous studies on hTR expression 
using RT-PCR method without DNase treatment.
HTR expression Type of cancer studied Ref.
58/62 (93.6%) Skin neoplasm 23
26/26 (100%) Stomach cancer 2
55/55 (100%) 32 normal human Endometrial and 23 
endometrial cancers
3
18/18 (100%) Prostate 4
34/34 (100%) Colonic cancer 11
11/11 (100%) Parathyroid lesions 12
20/20 (100%) Renal cell carcinoma 13
20/20 (100%) Ovarian adenocarcinoma 24
39/43 (90.7%) Nasopharyngeal carcinoma 25
42/45 (93.3%) Skin tumors 26
39/39 (100%)* Colorectal carcinoma 27*
*: DNase treatment was performed, but, the accuracy of DNase 
digestion and probable effect of remaining DNase activity on the 
genes PCR had not assayed.
Table 2: The frequency of telomerase activity between either 
sample with hTR expression or without expression.
HTR expression
Telomerase activity Positive Negative Total
Positive 60% (30)* 12% (6) 72% (36)
Negative 4% (2) 24% (12) 28% (14)
Total 64% (32) 36% (18) 50
*The outcomes presented as percentage (number). Chi-square = 
20.85, P < 0.001
Electrophoregram for GAPDH and hTR PCR products Figure 2
Electrophoregram for GAPDH and hTR PCR products. A: cDNA samples. B: Mixture of RNA and materials required 
for cDNA synthesis excluding Reverse Transcriptase enzyme, determining the probable DNA contamination. C: DNase 
treated cDNA. D: Mixture of DNased RNA and required for cDNA synthesis excluding Reverse Transcriptase enzyme, deter-
mining the accuracy of DNase treatment. All of samples had GAPDH expression but lanes 7 and 8 did not have expression of 
this gene (in RNA-RT samples) and so did not have DNA contamination. Lanes 1–3 had positive expression of hTR. Lanes 4–6 
did not have expression on DNased treated samples and so were negative but if we had not used DNase treatment, the 
expression was determined and this was caused by DNA contamination. Lane 7 did not have DNA contamination and the band 
seen in PCR for cDNA sample does not belong to DNA contamination. Lane 8 did not have any DNA contamination and hTR 
expression, too. C.-: Negative control including any cDNA or DNA template. C. +: Positive control (a template with positive 
expression of gene) to reach the accuracy of PCR. M: DNA size marker.Publish with BioMed Central    and   every 
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